Alivus Life Sciences Achieves Flawless USFDA Inspection at Dahej API Facility
Alivus Life Sciences' Active Pharmaceutical Ingredient (API) facility in Dahej, Gujarat, successfully completed a United States Food and Drug Administration (USFDA) inspection with zero Form 483 observations. This outcome validates the facility's adherence to Good Manufacturing Practices (GMP) and demonstrates the company's commitment to quality and regulatory compliance. The successful inspection potentially strengthens Alivus Life Sciences' position in the global pharmaceutical market, particularly for products destined for the U.S. market, and builds confidence among regulators, partners, and customers.
15May 25
Alivus Life Sciences Reports Strong Q4 Results, Recommends Dividend
Alivus Life Sciences announced robust Q4 financial results with significant year-over-year growth. Revenue increased by 21.3% to ₹6.50 billion, EBITDA grew by 40.4% to ₹1.98 billion, and net profit rose by 42.9% to ₹1.40 billion. The company's EBITDA margin expanded by 420 basis points to 30.56%. Additionally, Alivus recommended a dividend of ₹5 per equity share.
04Apr 25
Alivus Life Sciences Receives USFDA EIR with VAI Status for Ankleshwar Facility
Alivus Life Sciences Limited has received an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status from the USFDA for its API manufacturing facility in Ankleshwar, Gujarat. The inspection was conducted from January 27-31, 2025. The VAI status allows the company to continue operations while addressing minor issues, indicating substantial compliance with good manufacturing practices.
03Apr 25
Alivus Life Sciences to Acquire 9.21% Stake in Torrent Urja 19 for ₹156 Crore
Alivus Life Sciences Limited is acquiring a 9.21% stake in Torrent Urja 19 Private Limited for ₹156 crore. This strategic investment aims to increase renewable power usage in Alivus' operations, aligning with its goal to become carbon neutral by 2030. The acquisition will also help Alivus comply with Indian electricity laws for captive power users. The transaction involves equity shares at face value and is expected to complete within 6 months. Alivus has signed a Share Purchase cum Subscription Shareholders' Agreement and a Power Supply Agreement with Torrent Urja 19.